

CUSTOMER  
NUMBER 22852

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

1300 I STREET, N. W.  
WASHINGTON, DC 20005-3315

202 • 408 • 4000  
FACSIMILE 202 • 408 • 4400

WRITER'S DIRECT DIAL NUMBER:

(202) 408-4033

July 28, 2000

jc862 U.S. PRO  
09/628693

TOKYO

011 • 813 • 3431 • 6943

BRUSSELS

011 • 322 • 646 • 0353

ATTORNEY DOCKET NO. 03495-0193

**Box PATENT APPLICATION**  
**Assistant Commissioner for Patents**  
**Washington, D.C. 20231**

Re: New U.S. Patent Application  
Title: Detection of a Gene, *vatD*, Encoding an  
Acetyltransferase Inactivating Streptogamin  
Inventor(s): J. Haroche et al.

Sir:

We enclose the following papers for filing in the United States Patent and Trademark Office in connection with the above patent application.

1. Application - 48 pages, including 6 independent claim(s) and 41 claims total.
2. Drawings - 3 sheets of informal drawings (Figures 1-3).
3. Preliminary Amendment.
4. Request for Approval of Drawing Change.
5. A check for \$1,562.00 representing a \$690.00 filing fee and \$872.00 for additional claims fees.

Applicants claim the right to priority based on Provisional Patent Application No. 60/146,141 filed July 30, 1999.

This application is being filed under the provisions of 37 C.F.R. § 1.53(f).  
Applicant(s) await notification from the Patent and Trademark Office of the time set for filing the Declaration.

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Assistant Commissioner for Patents

July 28, 2000

Page 2


Please accord this application a serial number and filing date.

The Commissioner is hereby authorized to charge any additional filing fees due and any other fees due under 37 C.F.R. § 1.16 or § 1.17 during the pendency of this application to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

By:



Kenneth J. Meyers  
Reg. No. 25,146

KJM/SMP:  
Enclosures

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	
	)	
Julien HAROCHE et al.	)	
	)	
Serial No.: Not Yet Assigned	)	Group Art Unit: Not Yet Assigned
	)	
Filed: Concurrently herewith	)	Examiner: Not Yet Assigned
	)	
For: DETECTION OF A GENE, <i>vatD</i> ,	)	
ENCODING AN ACETYLTRANSFERASE	)	
INACTIVATING STREPTOGRAMIN	)	

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

**PRELIMINARY AMENDMENT**

Prior to examination of the above-identified application, please amend the application as follows.

**IN THE DRAWINGS:**

Please amend Figures 1 and 2 as indicated in the attached Request for Approval of Drawing Changes.

LAW OFFICES


FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

PATENT  
Attorney Docket No. 3495.0193

If there is any fee due in connection with the filing of this Preliminary  
Amendment, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

By:   
Kenneth J. Meyers  
Reg. No. 25,146

Date: July 28, 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	
	)	
Julien HAROCHE et al.	)	
	)	
Serial No.: Not Yet Assigned	)	Group Art Unit: Not Yet Assigned
	)	
Filed: Concurrently herewith	)	Examiner: Not Yet Assigned
	)	
For: DETECTION OF A GENE, <i>vatD</i> ,	)	
ENCODING AN ACETYLTRANSFERASE )		
INACTIVATING STREPTOGRAMIN )		

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

**REQUEST FOR APPROVAL OF DRAWING CHANGE**

Subject to the approval of the Examiner, it is respectfully requested that Figures 1 and 2 in the above-captioned application be amended by insertion of sequence identifiers SEQ ID NO:17 and SEQ ID NO:18 (Figure 1) and SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, and SEQ ID NO:18 (Figure 2) in the upper left-hand corners of the figures. The changes are indicated in red on the attached copy of the originally filed drawings.


LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

PATENT  
Attorney Docket No. 3495.0193

Upon approval of the proposed changes, Applicants respectfully request that the submission of revised drawings be deferred until after a notice of allowance has issued.

Respectfully submitted,  
FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

By:   
Kenneth J. Meyers  
Reg. No. 25,146

Date: July 27, 2000

SEQ ID NO. 17

1 CCCTTTAAAG AGGGCTTTTA TATATTAATC ACAAATCACT TATCACAAAT  
 51 CACAAGTGAT TTGTGATTGT TGATGATAAA ATAAGAATAA GAAGAAATAG  
 101 AAAGAAGTGA GTGATTGTGG GAAATTTAGG CGCACAAAAA GAAAGAGTGT  
 151 GACAAAACAT GGTTATGCTA CATGTTTAAG GTAAAAATAG TTATGTCACA  
 201 ACTACTTATT TTTTACCCA ATCTTCTAGA CTATAATTAA AATTAAATAA

XbaI

SEQ ID NO 18

251 CTCAATTCGG AGGTACTAAC ATGACTATAC CTGACGCAA TGCAATCTAT  
 301 CATAAATCAG CCATCAAAGA GGTGTCTTT ATCAAGAACG TGATCAAAAG  
 351 TCCCAATATT GAAATTGGGG ACTACACCTA TTATGATGAC CCAGTAAATC  
 401 CCACCGATTT TGAGAAACAC GTTACCCATC ACTATGAATT TCTAGGCGAC  
 451 AAATTAATCA TCGGTAAATT TTGTTCTCTC GCCAGTGGCA TTGAATTTAT  
 501 CATGAACGGT GCCAACCACG TAATGAAAGG TATTTCGACT TATCCATTTA  
 551 ATATATTAGG TGGCGATTGG CAACAATACA CTCCTGAAC TACTGATTTG  
 601 CCGTTGAAAG GTGATACTGT AGTCGGAAAT GACGTGTGGT TTGGGCAAAA  
 651 TGTGACCGTC CTACCAGGCG TAAAAATAGG TGACGGTGCC ATTATCGGAG  
 701 CAAATAGTGT TGTAACAAAA GACGTCGCTC CATATACAAT TGTCGGTGGC  
 751 AATCCAATTC AACTCATCGG ACCAAGATTT GAACCGGAAG TTATTCAAGC  
 801 ATTAGAAAAT CTGGCATGGT GGAATAAAGA TATTGAATGG ATAAGTCTA  
 851 ATGTTCTTAA ACTAATGCAA ACAACACCCA CACTTGAATT GATAAACAGT  
 L M E K \*  
 STOP  
 901 TTAATGGAAA AATAAAAAACA AAAAAGCCGT GCAAGCAATC CAAAAATGAT  
 951 TGTTTACACG GCGTTTACTA TTTAGTGAAT CCAATTTATT AATAATAGAT  
 1001 ATGATATACC AGTAAAAAAT AACTAGCCA CCTCTGGCGG TACTCTACTC  
 1051 GTATATTTTA TTTACGACCT TCTGATGATA

CCCTTTAAAG AGGGCTTTTA TATATTAATC ACAAATCACT TATCACAAAT  
 CACAAGTGAT TTGTGATTGT TGATGATAAA ATAAGAATAA GAAGAAATAG  
 AAAGAAGTGA GTGATTGTGG GAAATTTAGG CGCACAAAAA GAAAGAGTGT  
 GACAAAACAT GGTTATGCTA CATGTTTAAG GTAAAAATAG TTATGTCACA  
 ACTACTTATT TTTTACCCA ATCTTCTAGA CTATAATTAA AATTAAATAA  
 CTCAATTCGG AGGTACTAAC ATGACTATAC CTGACGCAA TGCAATCTAT  
 CATAAATCAG CCATCAAAGA GGTGTCTTT ATCAAGAACG TGATCAAAAG  
 TCCCAATATT GAAATTGGGG ACTACACCTA TTATGATGAC CCAGTAAATC  
 CCACCGATTT TGAGAAACAC GTTACCCATC ACTATGAATT TCTAGGCGAC  
 AAATTAATCA TCGGTAAATT TTGTTCTCTC GCCAGTGGCA TTGAATTTAT  
 CATGAACGGT GCCAACCACG TAATGAAAGG TATTTCGACT TATCCATTTA  
 ATATATTAGG TGGCGATTGG CAACAATACA CTCCTGAAC TACTGATTTG  
 CCGTTGAAAG GTGATACTGT AGTCGGAAAT GACGTGTGGT TTGGGCAAAA  
 TGTGACCGTC CTACCAGGCG TAAAAATAGG TGACGGTGCC ATTATCGGAG  
 CAAATAGTGT TGTAACAAAA GACGTCGCTC CATATACAAT TGTCGGTGGC  
 AATCCAATTC AACTCATCGG ACCAAGATTT GAACCGGAAG TTATTCAAGC  
 ATTAGAAAAT CTGGCATGGT GGAATAAAGA TATTGAATGG ATAAGTCTA  
 ATGTTCTTAA ACTAATGCAA ACAACACCCA CACTTGAATT GATAAACAGT  
 L M E K \*  
 STOP  
 TTAATGGAAA AATAAAAAACA AAAAAGCCGT GCAAGCAATC CAAAAATGAT  
 TGTTTACACG GCGTTTACTA TTTAGTGAAT CCAATTTATT AATAATAGAT  
 ATGATATACC AGTAAAAAAT AACTAGCCA CCTCTGGCGG TACTCTACTC  
 GTATATTTTA TTTACGACCT TCTGATGATA

FIGURE 1

Vat  
VatC  
SatA  
VatB  
VatD

Vat  
VatC  
SatA  
VatB  
VatD

Vat  
VatC  
SatA  
VatB  
VatD

[illegible][illegible]

```

IEEWLALQWNLDMKI INENLPETING--DIEMLRKRRLDDT
IALALKVRWMDLEIETINENIDCING--DIKKVRS-----
INQLDIKWWNPIDI INENIDKILDN--SIREVIMKK-----
IDYLLQIKWWDSAQKIFSNLETLCSS--DLEIKISIRD-----
IQALENLAWWNKDIEWITANVPKLMQTTPTLELINSIMEK-----
*      *      *      *      *      *      *

```

## FIGURE 2

Atty. Docket No: 03495.0193

UNITED STATES PATENT APPLICATION

OF

JULIEN HAROCHE

JEANINE ALLIGNET

AND

NEVINE EL SOLH

FOR

DETECTION OF A GENE, *vatD*, ENCODING AN  
ACETYLTRANSFERASE INACTIVATING STREPTOGRAMIN

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

BACKGROUND OF THE INVENTION

This application claims the right to priority based on Provisional Patent Application No. 60/146,141 filed July 30, 1999. The entire disclosure of Provisional Patent Application No. 60/146,141 is hereby incorporated by reference.

This invention relates to the discovery of a new gene, *vatD*, encoding an acetyltransferase inactivating streptogramin A, which is widely distributed in virginiamycin-resistant *enterococcus faecium* strains.

Streptogramin, virginiamycin, pristinamycin, and synergistin are produced by streptomyces, and consist of synergistic mixtures of two chemically different molecules: A and B compounds (10). In some European countries and in Algeria, these mixtures are used both orally and topically, mostly against staphylococcal infections. Virginiamycin is used as growth promoter in animal feed in Europe and in the U.S.A. Virginiamycin-resistant *Enterococcus faecium* are prevalent in fecal and intestinal samples from turkeys, pigs, broilers, and farmers in Europe and America (1, 14, 19, 20). Since bacteria can be transferred via food from animals to humans, this is alarming, in particular because quinupristin/dalfopristin (J. Antimicrob. Agents Chemother., 1992, 30[suppl.30]), an injectable mixture of semi-synthetic streptogramins soon to be commercialized (Synercid), is expected to be widely used, mainly to treat vancomycin-resistant *E. faecium* infections.

The *sata* gene (18) encoding an acetyltransferase inactivating A compounds was isolated from an *E. faecium*

5 plasmid. It was found in only 29 % of the 140 tested  
*E. faecium* strains isolated in Dutch and Danish farms and  
resistant to the mixtures (13, 14). Five of the *E.*  
*faecium* strains isolated in Denmark harbored a large  
10 plasmid conferring resistance to the mixture and which  
was transferable by filter mating experiments to an *E.*  
*faecium* recipient (14). None of the transconjugants  
harboring these plasmids carried *satA*, *vat*, *vatB*, *vga*, or  
*vgaB* (14). These results suggested that the *E. faecium*  
strains contained other unidentified streptogramin A  
resistance gene(s). Thus, there continues to exist a  
need in the art for the identification of new genes  
specific for *Enterococcus faecium* resistant to  
streptogramin A and related compounds.

#### 15 SUMMARY OF THE INVENTION

Accordingly, this invention aids in fulfilling this  
need in the art by providing a new gene, *vatD*, encoding  
an acetyltransferase inactivating Streptogramin A, which  
is widely distributed in virginiamycin-resistant  
20 *Enterococcus faecium* strains. In particular, this  
invention provides a purified peptide-comprising the  
complete amino acid sequence (SEQ ID NO:1) encoded by the  
*vatD* gene. This invention also provides polypeptide  
fragments derived from SEQ ID NO:1 containing at least 10  
25 amino acids. The fragments can be common to all  
virginiamycin A acetyl transferases as shown on SEQ ID  
NOS:5, 6, 7, and 8. The fragments according to the  
invention can be specific of as shown on SEQ ID NOS:9,  
10, 11, and 12.

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

This invention additionally provides a purified polynucleotide comprising the complete nucleic acid sequence of the *vatD* gene (SEQ ID NO:2). This invention also provides nucleic acid fragments derived from SEQ ID NOS:3 and 4 containing 15 to 40 nucleotides as primers F and R. For example, the fragments are those corresponding to nucleotides No. 899 to 878 and to nucleotides No. 354 to nucleotide 378. (Fig. 1)

In addition, two primers have been selected in order to obtain, after using an amplification technique and after cloning the amplified sequence, the complete gene of *vatD* capable of being expressed in *Staphylococcus aureus* (strain No. 4220 described by KREISWIRTH et al. in Nature 1983, Vol. 306, pp. 709-712]. These primers are shown in SEQ ID NOS:13 and 14 as *vatDA* and *vatDB*. The *vatDA* is from nucleotide 98 to nucleotide 120 (Figure 1). The *vatDB* is from nucleotide 982 to nucleotide 957 (Figure 1).

In SEQ ID NOS:13 and 14, an artificial site was created if comparing with the original sequence in Figure 1 at nucleotides No. 107 and 109 where G was replaced by T and G was replaced by C, respectively. An *EcoRI* site was then produced in the first primer. In the same manner, in SEQ ID NOS:3 and 4, at nucleotide No. 362, A replaces G (as in the original sequence) and at nucleotide 367, C replaces G (as in the original sequence). A new *EcoRI* site was created. In the second primer of SEQ ID NOS:3 and 4, a new *EcoRI* site was created by replacing at nucleotide No. 891 G by C and on the complementary strand (as shown) the base C (original) is replaced by G.

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, DC 20005  
202-408-4000

This invention also provides a composition comprising purified polynucleotide sequences including at least one nucleotide sequence of the genes selected from the group consisting of synthetic polynucleotides or fragments of genes or cDNA of *vatD* useful for the detection of resistance to streptogramin A and related compounds. The gene *vatD* was obtained from a *Hind*III fragment of 5 kb prepared from *enterococcus faecium* genome (strain K14) after digestion by *Hind*III restriction enzyme. The *Hind* III fragment hybridizes with an amplicon containing two degenerated or consensus primers referred to as M and N, which are defined as SEQ ID NOS:5, 6, 7, and 8. This amplicon has 147 nucleotides. The amplicon or the two degenerated primers (M and N) can be used for the preparation of DNA chips as taught in PCT applications No. W095.11.995 and No. WO 97.02.357. The sequences upstream and downstream of this amplicon were obtained.

The DNA fragment containing the *vatD* gene including the amplicon is shown in Figure 1. A region having in this said fragment, the possible properties of a bacterial promoter activity is located as follows in Figure 1. Its sequence is:

-35  
TGTCACA  
-10

201 ACTACTTATT TTTTACCCA ATCTTCTAGA CTATAAT  
XbaI

(SEQ ID NO:16)

Additionally, the invention includes a purified polynucleotide that hybridizes specifically under

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

stringent conditions with a polynucleotide of SEQ ID NOS:  
2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12.

5 The invention further includes polynucleotide  
fragments comprising at least 10 nucleotides capable of  
hybridization under stringent conditions with any one of  
the nucleotide sequences enumerated above.

10 In another embodiment of the invention, a  
recombinant DNA sequence comprising at least one  
nucleotide sequence enumerated above and under the  
control of regulatory elements that regulate the  
expression of resistance to antibiotics of the  
streptogramin family in a defined host is provided. The  
amplified complete gene of vatD, including the amplicon  
and the promoter, is shown in SEQ ID NO:15.

15 Furthermore, the invention includes a recombinant  
vector comprising the recombinant DNA sequence noted  
above, wherein the vector comprises the plasmid pIP 1801  
contained in *E. coli*. The recombinant strain has been  
deposited at the collection C.N.C.M. in Paris, France,  
20 under the accession number I-2247 on July 7, 1999.

The invention also includes a recombinant cell host  
comprising a polynucleotide sequence enumerated above or  
the recombinant vector defined above.

25 In still a further embodiment of the invention, a  
method detecting bacterial strains that contain the  
polynucleotide sequences set forth above is provided.

Additionally, the invention includes kits for the  
detection of the presence of bacterial strains that  
contain the polynucleotide sequences set forth above.

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

The invention also contemplates antibodies recognizing peptide fragments or polypeptides encoded by the polynucleotide sequences enumerated above.

Still further, the invention provides for a screening met for active antibiotics and/or molecules for the treatment of infections due to Gram-positive bacteria, particularly enterococci, based on the detection of activity of these antibiotics and/or molecules on bacteria having the resistance phenotype to streptogramins.

#### BRIEF DESCRIPTION OF THE DRAWINGS

This invention will be more fully described with reference to the drawings in which:

FIGURE 1 discloses the complete nucleotide and amino acid sequences of *vatD*. In this Figure are also represented the upstream and downstream regions of the *vatD* gene.

FIGURE 2 is a comparison between the sequences of *vatD* protein and four acetyltransferase enzymes already published.

FIGURE 3 is a restriction map of the insert of 1080 bp contained in the plasmid deposited in *E. coli* at C.N.C.M. I-2247.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention pertains to polynucleotides derived from *Enterococcus faecium* genes encoding resistance to streptogramin A and chemically related compounds. This invention also relates to the use of the polynucleotides as oligonucleotide primers or probes for

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

detecting *Enterococcus faecium* strains that are resistant to streptogramin A and related compounds in a biological sample.

5 In another embodiment, the present invention is directed the full length coding sequences of the *Enterococcus faecium* genes encoding resistance to streptogramin A and to the polypeptides expressed by these full length coding sequences.

10 Further, this invention relates to the use of the expressed polypeptides to produce specific monoclonal or polyclonal antibodies that serve as detection means in order to character any *Enterococcus faecium* strain carrying genes encoding resistance to streptogramin A and chemically related compounds

15 The present invention is also directed to diagnostic method for detecting specific strains of *Enterococcus faecium* expected to be contained in a biological sample. The diagnostic methods use the oligonucleotide probes and primers as well as the antibodies of the invention.

20 More particularly, it has now been determined that bacteria from the *Enterococcus faecium* genus carry a *vatD* gene, which confers resistance to streptogramin A. A gene encoding an acetyltransferase inactivating streptogramin A was isolated from an *Enterococcus faecium*  
25 strain and sequenced. The gene, designated *vatD*, encodes a 23,775 kDa protein exhibiting 48.5 to 59.9 % amino acid identity with four other enzymes with the same activity,

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

vat, vatB, vatC, and satA. The calculation of the percentage of identity was made by using the program gap of GCG software (version 9.1). The parameters are chosen as follows:

- 5           a)   for amino acid comparisons:  
            gap penalty:    12  
            gap extension penalty:    4  
            length:   the sequence to be compared in SEQ ID  
                            NO:1 having 213 amino acids.
- 10           b)   for nucleotide comparisons:  
            gap penalty:    50  
            gap extension penalty:    3.

Figure 2 shows the comparative amino acid alignments of vatD with four virginiamycin A acetyl transferase proteins. The satB protein is from *Enterococcus*, and vat, vatB, and vatC are from *Staphylococcus*.

Novel polynucleotides corresponding to the vatD gene from various strains of *Enterococcus faecium* have been isolated and sequenced. These polynucleotides include SEQ ID NO:2. By "polynucleotides" according to the invention is meant the sequence referred to as SEQ ID NO:2, and the complementary sequences and/or the sequences of polynucleotides that hybridize to the referred sequences in high stringent conditions (hybridization in a mixture containing 5 x SSPE, 5x Denhart solution, 0.5% SDS (w/v) and 100 µg/ml salmon sperm DNA]. The membrane on which is hybridized the DNA, is washed 2 times during 10 minutes, in 2x SSPE, 0.1% SDS (w/v) at room temperature and then the membrane (or the filter) is immersed in a solution of 1 x SSPE, 0.1% SDS (w/v) during 15 minutes at 68°C and finally in a

solution of 1 x SSPE, 0.1% SDS (w/v) during 15 minutes at 68°C. The polynucleotides according to the invention are used for detecting *Enterococcus faecium* strains carrying a gene encoding resistance to streptogramin A.

5 By "active molecule" according to the invention is meant a molecule capable of inhibiting the activity of the purified polypeptide as defined in the present invention or capable of inhibiting the bacterial culture of *Enterococcus faecium* strains.

10 Thus, the polynucleotides of SEQ ID NO:2 and its fragment can be used to select nucleotide primers notably for an amplification reaction, such as the amplification reactions further described. PCR is described in the U.S. Patent No. 4,683,202 granted to Cetus Corp. The  
15 amplified fragments may identified by agarose or polyacrylamide gel electrophoresis, or by a capillary electrophoresis, or alternatively by a chromatography technique (gel filtration, hydrophobic chromatography, or ion exchange chromatography). The specificity of the  
20 amplification can be ensured by a molecular hybridization using as nucleic probes the polynucleotides derived from SEQ ID NO:2 and its fragments, oligonucleotides that are complementary to these polynucleotides or fragments thereof, or their amplification products themselves.

25 Amplified nucleotide fragments are useful as probes in hybridization reactions in order to detect the presence of one polynucleotide according to the present invention or in order detect the presence of a bacteria of *Enterococcus faecium* strain carrying genes encoding resistance to streptogramin A, in a biological sample. This invention also provides, the amplified nucleic acid

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, DC 20005  
202-408-4000

fragments ("amplicons") defined herein above. These probes and amplicons can be radioactively or non-radioactively labeled, using for example enzymes or fluorescent compounds.

5 Preferred nucleic acid fragments that can serve as primers according to the present invention are the following in the Fig. 1:

PRIMER F 5' -CAATATTGGAATTCGGGACTACACC-3' (SEQ ID NO:3)  
EcoRI

10 nt 354 nt 378 gene vatD

PRIMER R 5' -CTGTTTATGAATTCAAGTGTGG-3' (SEQ ID NO:4)  
EcoRI

nt 899 nt 878 gene vatD

The primers can also be used as oligonucleotide probes to specifically detect a polynucleotide according to the invention.

15 Other techniques related to nucleic acid amplification can also be used and are generally preferred to the PCR technique. The Strand Displacement Amplification (SDA) technique (Walker et al., 1992) is an isothermal amplification technique based on the ability of a restriction enzyme to cleave one of the strands at a recognition site (which is under a hemiphosphorothioate form), and on the property of a DNA polymerase to  
20 initiate the synthesis of a new strand from the 3' OH end generated by the restriction enzyme and on the property of this DNA polymerase to displace the previously synthesized strand being localized downstream.

25 The SDA amplification technique is more easily performed than PCR (a single thermostated water bath device is necessary and is faster than the other

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

amplification methods. Thus, the present invention also comprises using the nucleic acid fragment according to the invention (primers) in a method of DNA or RNA amplification according to the SDA technique. The polynucleotides of SEQ ID NO:2 and its fragments, especially the primers according to the invention, are useful as technical means for performing different target nucleic acid amplification methods such as:

- TAS (Transcription-based Amplification System), described by Kwoh et al. in 1989;
- SR (Self-Sustained Sequence Replication), described by Guatelli et al. in 1990;
- NASBA (Nucleic acid Sequence Based Amplification), described by Kievitis et al. in 1991; and
- TMA (Transcription Mediated Amplification).

The polynucleotides of SEQ ID NO:2 and its fragments, especially the primers according to the invention, are also useful as technical means for performing methods for amplification or modification of a nucleic acid used as a probe, such as:

- LCR (Ligase Chain Reaction), described by Landegren et al. in 1988 and improved by Barany et al. in 1991, who employ a thermostable ligase;
- RCR (Repair Chain Reaction), described by Segev et al. 1992;
- CPR (Cycling Probe Reaction), described by Duck et al. in 1990; and
- Q-beta replicase reaction, described by Miele et al. in 1983 and improved by Chu et al. in 1986, Lizardi et al. in 1988 and by Burg et al. and Stone et al. in 1996.

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, DC 20005  
202-408-4000

When the target polynucleotide to be detected is RNA, for example mRNA, a reverse transcriptase enzyme can be used before the amplification reaction in order to obtain a cDNA from the RNA contained in the biological sample. The generated cDNA can be subsequently used as the nucleic acid target for the primers or the probes used in an amplification process or a detection process according to the present invention.

Nucleic probes according to the present invention are specific to detect a polynucleotide of the invention. By "specific probes" according to the invention is meant any oligonucleotide that hybridizes with the polynucleotide of SEQ ID NO:2, and which does not hybridize with unrelated sequences. Preferred oligonucleotide probes according to the invention are SEQ ID NOS:5, 6, 7, or 8 or SEQ ID NOS:3 or 4.

In a specific embodiment, the purified polynucleotides according to the present invention encompass polynucleotides having at least 80% identity in their nucleic acid sequences with polynucleotide of SEQ ID NO:2. By percentage of nucleotide homology according to the present invention is intended a percentage of identity between the corresponding bases of two homologous polynucleotides, this percentage of identity being purely statistical and the differences between two homologous polynucleotides being located at random and on the whole length of said polynucleotides. The calculation was made according to the software GCG and the program "gap."

The oligonucleotide probes according to the present invention hybridize specifically with a DNA or RNA

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, DC 20005  
202-408-4000

5 molecule comprising all or part of the polynucleotide of  
SEQ ID NO:2 under stringent conditions. As an  
illustrative embodiment, the stringent hybridization  
conditions used in order to specifically detect a  
polynucleotide according to the present invention are  
advantageously the following:

Prehybridization and hybridization are performed at  
68°C a mixture containing:

- 5X SSPE (1X SSPE is .3 M NaCl, 30 mM tri-  
sodium citrate
- 5X Denhardt's solution
- 0.5% (w/v) sodium dodecyl sulfate (SDS); and
- 100  $\mu\text{g ml}^{-1}$  salmon sperm DNA

The washings are performed as follows:

- Two washings at laboratory temperature for 10  
min. in the presence of 2 x SSPE and 0.1 % SDS;
- One washing at 68°C for 15 min. in the  
presence of 1 x SSPE, .1% SDS; and
- One washing at 68°C for 15 min. in the  
presence of 0.1 x SSPE and 0.1 % SDS.

The non-labeled polynucleotides or oligonucleotides  
of the invention can be directly used as probes.  
Nevertheless, the polynucleotides or oligonucleotides are  
generally labeled with radioactive element ( $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^3\text{H}$ ,  
 $^{125}\text{I}$ ) or by a non-isotopic molecule (for example, biotin,  
acetylaminofluorene, digoxigenin, 5-bromodesoxyuridin,  
fluorescein) in order to generate probes that are useful  
for numerous applications. Examples of non-radioactive  
labeling of nucleic acid fragments are described in the  
French Patent No. FR 78 10975 or by Urdea et al. or  
Sanchez Pescador et al. 1988.

Other labeling techniques can also be used, such as those described in the French patents 2 422 956 and 2 518 755. The hybridization step may be performed in different ways (Matthews et al. 1988). A general method comprises immobilizing the nucleic acid that has been extracted from the biological sample on a substrate (nitrocellulose, nylon, polystyrene) and then incubating, in defined conditions, the target nucleic acid with the probe. Subsequent to the hybridization step, the excess amount of the specific probe is discarded, and the hybrid molecules formed are detected by an appropriate method (radioactivity, fluorescence, or enzyme activity measurement).

Advantageously, the probes according to the present invention can have structural characteristics such that they allow signal amplification, such structural characteristics being, for example, branched DNA probes as those described by Urdea et al. in 1991 or in the European Patent No. 0 225 807 (Chiron).

In another advantageous embodiment of the present invention, the probes described herein can be used as "capture probes", and are for this purpose immobilized on a substrate in order to capture the target nucleic acid contained in a biological sample. The captured target nucleic acid is subsequently detected with a second probe, which recognizes a sequence of the target nucleic acid that is different from the sequence recognized by the capture probe.

The oligonucleotide fragments useful as probes or primers according to the present invention can be prepared by cleavage of the polynucleotide of SEQ ID NO:2

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, DC 20005  
202-406-4000

by restriction enzymes, as described in Sambrook et al. in 1989. Another appropriate preparation process of the nucleic acids of the invention containing at most 200 nucleotides (or 200 bp if these molecules are double-stranded) comprises the following steps:

- synthesizing DNA using the automated method of beta-cyanethylphosphoramidite described in 1986;
- cloning the thus obtained nucleic acids in an appropriate vector; and
- purifying the nucleic acid by hybridizing to an appropriate probe according to the present invention.

A chemical method for producing the nucleic acids according to the invention, which have a length of more than 200 nucleotides (or 200 bp if these molecules are double-stranded) comprises the following steps:

- Assembling the chemically synthesized oligonucleotides having different restriction sites at each end;
- cloning the thus obtained nucleic acids in an appropriate vector; and
- purifying the nucleic acid by hybridizing to an appropriate probe according to the present invention.

The oligonucleotide probes according to the present invention can also be used in a detection device comprising a matrix library of probes immobilized on a substrate, the sequence of each probe of a given length being localized in a shift of or several bases, one from the other, each probe of the matrix library thus being complementary to a distinct sequence of the target

nucleic acid. Optionally, the substrate of the matrix can be a material able to act as an electron donor, the detection of the matrix positions in which hybridization has occurred being subsequently determined by an electronic device. Such matrix libraries of probes and methods of specific detection of a target nucleic acid are described in the European patent application No. 713 016, or PCT Application No. WO 95 33846, or also PCT Application No. WO 95 11995 (Affymax Technologies), PCT Application No. WO 97 02357 (Affymetrix Inc.), and also in U.S Patent No. 5,202,231 (Drmanac), said patents and patent iapplications being herein incorporated by reference.

The present invention also pertains to a family of recombinant plasmids containing at least a nucleic acid according to the invention. According to an advantageous embodiment, a recombinant plasmid comprises a polynucleotide of SEQ ID NO:2 or nucleic acid fragment thereof. More specifically, the following plasmid is part of the invention: pIP1801 or its fragments. Said fragments are derived from the use of restriction enzymes according to the restriction map of the gene vatD, as shown in Figure 3.

The present invention is also directed to the full length coding sequences of the vatD gene from *Enterococcus faecium* available using the purified polynucleotides according to the present invention, as well as to the polypeptide enzymes encoded by these full length coding sequences. In a specific embodiment of the present invention, the full length coding sequence of the vatD gene is isolated from a plasmid or cosmid library of

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, DC 20005  
202-408-4000

the genome of *Enterococcus faecium* that has been screened with the oligonucleotide probe according to the present invention. The selected positive plasmid or cosmid clones hybridizing with the oligonucleotide probes of the invention are then sequenced in order to characterize the corresponding full length coding sequence, and the DNA insert of interest is then cloned in an expression vector conferring resistance to streptogramin A and related compounds.

A suitable vector for the expression in bacteria and in particular in *E. coli*, is the pQE-30 vector (QIAexpress) that allows the production of a recombinant protein containing a 6xHis affinity tag. The 6xHis tag is placed at the C-terminus of the recombinant polypeptide ATP binding motif conferring resistance to streptogramin A and related compounds.

The polypeptides according to the invention can also be prepared by conventional methods of chemical synthesis, either in a homogenous solution or in solid phase. As an illustrative embodiment of such chemical polypeptide synthesis techniques the homogenous solution technique described by Houbenweyl in 1974 may be cited.

The polypeptide conferring resistance to streptogramin A and related compounds is useful for the preparation of polyclonal or monoclonal antibodies that recognize the polypeptides or fragments thereof. The monoclonal antibodies can be prepared from hybridomas according to the technique described by Kohler and Milstein in 1975. The polyclonal antibodies can be prepared by immunization of a mammal, especially a mouse or a rabbit, with a polypeptide according to the

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, DC 20005  
202-408-4000

invention that is combined with an adjuvant, and then by purifying specific antibodies contained in the serum of the immunized animal on a affinity chromatography column on which has previously been immobilized the polypeptide that has been used as the antigen.

Consequently, the invention is also directed to a method detecting specifically the presence of a polypeptide according to the invention in a biological sample. The method comprises:

- a) bringing into contact the biological sample with an antibody according to the invention; and
- b) detecting antigen-antibody complex formed.

Also part of the invention is a diagnostic kit for *in vitro* detecting the presence of a polypeptide according to the present invention in a biological sample. The kit comprises:

- a polyclonal or monoclonal antibody as described above, optionally labeled; and
- a reagent allowing the detection of the antigen-antibody complexes formed, wherein the reagent carries optionally a label, or being able to be recognized itself by a labeled reagent, more particularly in the case when the above-mentioned monoclonal or polyclonal antibody is not labeled by itself.

Indeed, the monoclonal or polyclonal antibodies according to the present invention are useful as detection means in order to identify or characterize a *Staphylococcal* strain carrying gene encoding resistance to streptogramin A.

The invention also pertains to:

- A purified polypeptide or a peptide fragment having at least 10 amino acids, which is recognized by antibodies directed against a polynucleotide sequence conferring resistance to streptogramin and related compounds, corresponding to a polynucleotide sequence according to the invention.

- A polynucleotide comprising the full length coding sequence of a *Enterococcus faecium* streptogramin A resistant gene containing a polynucleotide sequence according to the invention.

- A monoclonal or polyclonal antibody directed against a polypeptide or a peptide fragment encoded by the polynucleotide sequences according to the invention.

- A method of detecting the presence of bacterium harboring the polynucleotide sequences according to the invention in a biological sample comprising:

- a) contacting bacterial DNA of the biological sample with a primer or a probe according to the invention, which hybridizes with a nucleotide sequence encoding resistance to streptogramins;
- b) amplifying the nucleotide sequence using said primer or said probe; and
- c) detecting the hybridized complex formed between said primer or probe with the DNA.

A kit for detecting the presence of bacterium having resistance to streptogramin A and harboring the polynucleotide sequences according to the invention in a biological sample, said kit comprising:

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, DC 20005  
202-408-4000

a) a polynucleotide probe according to the invention; and

b) reagents necessary to perform a nucleic acid hybridization reaction.

5 A kit for detecting the presence of bacterium having resistance to streptogramin A and harboring the polynucleotide sequences according to the invention in a biological sample, said kit comprising:

10 a) a polynucleotide probe according to the invention; and

b) reagents necessary to perform a nucleic acid hybridization reaction.

15 A method of screening active antibiotics for the treatment of the infections due to Gram-positive bacteria, comprising the steps of:

a) bringing into contact a Gram-positive bacteria having a resistance to streptogramin A and related compounds and containing the polynucleotide sequences according to the invention with the antibiotic; and

20 b) measuring an activity of the antibiotic on the bacteria having a resistance to streptogramins and related compounds.

25 A method of screening for active synthetic molecules capable of penetrating into a bacteria of the family of enterococcus, wherein the inhibiting activity of these molecules is tested on at least a polypeptide encoded by the polynucleotide sequences according to the invention comprising the steps of:

a) contacting a sample of said active molecules with the bacteria;

b) testing the capacity of the active molecules to penetrate into the bacteria and the capacity of inhibiting a bacterial culture at various concentration of the molecules; and  
c) choosing the active molecule that provides an inhibitory effect of at least 80% on the bacterial culture compared to an untreated culture.

An *in vitro* method of screening for active molecules capable of inhibiting a polypeptide encoded by the polynucleotide sequences according to the invention, wherein the inhibiting activity of these molecules is tested on at least said polypeptide, said method comprising the steps of:

- a) extracting a purified polypeptide according to the invention;
- b) contacting the active molecules with said purified polypeptide;
- c) testing the capacity of the active molecules, at various concentrations, to inhibit the activity of the purified polypeptide; and
- d) choosing the active molecule that provides an inhibitory effect of at least 80 % on the activity of the said purified polypeptide.

In the inactivation by the O-acetylation of virginiamycin A mediated by *vatD*, the donor of acetyl group is probably acetyl coenzyme A. The acetylation reduced coenzyme A can react with 55'-dithio bis 2 nitrobenzoate (DTNB) to yield 5 thio 2 nitrobenzoate with a 1:1 stoichiometry. The 5 thio 2 nitrobenzoate is

yellow and has a high extinction coefficient ( $E = 00136 \text{ mM}^{-1} \text{ cm}^{-1}$ ) at  $\lambda 412 \text{ nm}$ . Therefore, the measurement of its appearance can be recorded by a spectrophotometer with great sensitivity.

5 As examples there are disclosed hereinafter the detection of chloramphenicol acetyl transferase activity. Similar conditions may be used for the detection of virginiamycin A activity to yield 5-thio-2-nitrobenzoate with a 1:1 stoichiometry. The thio-2-nitrobenzoate is  
10 yellow and has a high extinction coefficient ( $00136 \text{ mM}^{-1} \text{ cm}^{-1}$ ) at  $\lambda 412 \text{ nm}$ . Therefore, the measurement of its appearance can be recorded spectrophotometrically with great sensitivity.

#### Materials

- 15 - Bacterial strain(s) to be tested.
- Mueller-Hinton (MH) broth (Gram-negative bacteria) or brain heart infusion (BHI) broth (Gram-positive cocci)
- 50 ml centrifuge tubes
- 20 - Eppendorf tubes
- Low speed centrifuge
- Refrigerated bench centrifuge
- Sonicator
- Double beam recording spectrophotometer  
25 equipped with a water jacketed cuvette
- Tris-Cl 1M (pH 6.0)
- Tris-Cl 1M (pH 7.8)
- Dithiothreitol (DTT) 0.01 M
- TDTT buffer: Tris-Cl 50 mM (pH 7.8)

DTT 20  $\mu\text{M}$

- Acetyl coenzyme A (CoASAc) 10 mM (PH 6.0) :  
dissolve 8.2 mg of CoASAc in 1 ml of 5 mM Tris-  
Cl (pH 6.0). This solution can be stored  
frozen for 1 year in aliquots (100  $\mu$ l).
- 5 - 5, 5'-dithiobis-2-nitrobenzoic acid (DTNB) 10  
mM (PH 7.8) : dissolve 20  $\mu$ g of DTNB in 0.5 ml  
of 1 M Tris-Cl (pH 7.8) and add 4.5 ml of  
distilled water. This solution should be make  
fresh each time.
- 10 - Reaction mixture: CoASAc (10 mM, pH 6.0):100 $\mu$ l  
DTNB (10 mM, PH 7.8) :500  $\mu$ l  
Tris-Cl (1 M, PH 7.8):920  $\mu$ l  
H<sub>2</sub>O up to 10 ml

This volume is sufficient for 15

15 reactions.

- Chloramphenicol (Cm) 10 mM (pH 7.8): dissolve  
3.2 mg of Cm in 1 ml of 100 mM Tris-Cl (pH  
7.8). heat 10 min in water bath at 100°C.  
Store at +4°C.

20 **Protocol**

**Day 1**

1. Inoculate separately 5 ml of MH broth with  
bacterial strains to be tested. Grow overnight at 37°C  
with moderate shaking.

25 **Day 2**

2. Inoculate separately 35 ml of MH broth with 1  
ml of each overnight culture. Grow at 37°C  
with moderate shaking until the OD<sub>600nm</sub> is 0.8.
3. Centrifuge the cells (8000 rpm, 10 min, 4°C).  
Discard the supernatant and wash the pellet in  
1 ml of TDDT buffer. Centrifuge again and

resuspend the pellet in 1 ml of the same buffer.

4. Sonicate the cells at 4°C with 5 x 30 s pulses with 30 s rest in between.
5. Centrifuge the samples in an Eppendorf centrifuge (15000 rpm, 10 min, 4°C) to remove cell debris.
6. Transfer supernatants (S20) to other Eppendorf tubes and keep on ice until assayed. If the CAT assay is not performed on the same day, freeze the samples at -20°C. The CAT activity can be retained frozen for at least one month.
7. Pour 600 µl of reaction mixture to reference cuvette and sample cuvettes equilibrated at 37°C in a double beam recording spectrophotometer. let stand 2 min ar adjust OD<sub>412nm</sub> to 0.
8. Add 20 µl of S20 to sample cuvettes, mix well, and record OD<sub>412nm</sub> for 1-2 min to determine the background CAT activity.
9. When a constant slope is obtained, add 10 µl of Cm to cuvettes, mix well and record the increase in absorbence (OD<sub>412nm</sub>) for about 5 min. If the CAT activity is too high, a more reliable measure of activity can be obtained by diluting the S20.
10. Measure the amount of protein in the S20.
11. Determine the slope (OD<sub>412nm</sub>/min) before and after adding Cm and then subtract the background slope from the sample slope. The CAT enzyme specific activity expressed in

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, DC 20005  
202-408-4000

nmole/min/mg is  $\Delta OD_{412nm}/0.0136/\text{mg protein}$   
 [0.0136 being the extinction coefficient ( $\text{mM}^{-1}\text{cm}^{-1}$   $\lambda_{412nm}$ ) of 5-thio-2-nitrobenzoate].

**Notes**

- 5                   - Since the formation of 5-thio-2-nitrobenzoate is accompanied by the appearance of a yellow coloration, CAT activity can be qualitatively appreciated *de visu* in step 9.
- 10                  - The crude extracts (S20) obtained from certain bacterial genera contain high thioesterase activity that may mask that of CAT since it also catalyzes the formation of reduced coenzyme A. On the
- 15                   other hand, DTNB was reported to inhibit certain CTAs from Gram-negative bacteria. In both cases, partial purification of the enzyme or the use of an alternate
- 20                   procedure is necessary to overcome these problems. Different methods for convenient CAT assays based on labelled acetyl
- coenzyme A (or butyryl coenzyme A) for acyl donor are available.
- 25                   - Chloramphenicol analogs, such as 3'-desoxychloramphenicol, can be used to induce CAT expression in Gram-positive bacteria. This compound is not acetylated by CATs (free inducer) and has little effect on protein synthesis.
- Medium containing carbohydrates other than glucose may be used for the growth of

Gram-negative bacteria to avoid catabolic repression.

If an active molecule for inhibiting the activity of the bacterial enzyme (acetyl transferase) is added to a culture medium containing the resistant strain, the acetyl co-enzyme A present in said medium is not degraded. If the molecule to be tested is not active on the resistant bacteria, the amount of acetyl co-enzyme A decreases.

A test for screening the inhibiting activity of a molecule, for example, a new antibiotic or a new antibacterial agent, can comprise the following steps:

- a) adding purified active acetyl transferase vatD in a solution containing virginiamycin A at various concentrations, acetyl co-enzyme A,
- b) adding the molecule to be tested at various concentrations,
- c) revealing the presence of acetyl co-enzyme A activity and quantifying said acetyl coenzyme A, if necessary, and
- d) comparing the quantification of acetyl coenzyme A with a control without the new molecule.

A composition of a polynucleotide sequence encoding resistance to streptogramins and related compounds, or inducing resistance in Gram-positive bacteria, wherein said composition comprises a nucleotide sequence corresponding to the resistance phenotype of the plasmid pIP1807 deposited with the C.N.C.M. under the Accession No. I-2247 on July 7, 1999.

A method of detecting the presence of bacterium harboring the polynucleotide sequences according to the

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, DC 20005  
202-408-4000

invention in a biological sample, said method comprising the steps of:

- 5           a)    contacting said sample with an antibody according to the invention that recognizes a polypeptide encoded by said polynucleotide sequences; and
- b)    detecting said complex.

10           A diagnostic kit for *in vitro* detecting the presence of bacterium harboring the polynucleotide sequences according to invention in a biological sample, said kit comprising:

- 15           a)    a predetermined quantity of monoclonal or polyclonal antibodies according to the invention;
- b)    reagents necessary to perform an immunological reaction between the antibodies and a polypeptide encoded by said polynucleotide sequences; and
- 20           c)    reagents necessary for detecting said complex between the antibodies and the polypeptide encoded by said polynucleotide sequences.

25           Plasmids containing the polynucleotides from *Enterococcus faecium*, which confer streptogramin A resistance have been inserted into vectors, which have been deposited at the Collection Nationale de Cultures de Microorganismes ("C.N.C.M.") Institut Pasteur, 28, rue du Docteur Roux, 75724 Paris Cedex 15 France on July 7, 1999, as follows:

Plasmid  
pIP1801

Accession No.  
I-2247

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, DC 20005  
202-408-4000

This invention will now be described in greater detail in the following Example.

Example

A collection of 51 *E. faecium* strains was studied for resistance to streptogramins. The strains were isolated from fecal samples from poultry (n = 22), pigs (n = 5), farmers (n = 19) and (sub)urban residents (n = 5) in the Netherlands (Table 1). *sata* was previously found in 19 strains and *vgb* in a single strain by PCR (14). The *E. faecium* strains were analyzed for nucleotide sequences hybridizing at high stringency (65°C) with the eight genes previously found in staphylococcal and enterococcal plasmids conferring resistance to the mixtures: *sata* (18), *vat* (9), *vatB* (3), *vatC* (6), *vga* (7) and *vgaB* (4) conferring resistance to A compounds and the two genes, *vgb* (8) and *vgbB*(6), encoding lactonases hydrolyzing B compounds. Nineteen of the strains carried *sata* and the combination of *vat* and *vgb* was detected in a single strain, KH6 (Table 1). These two latter genes are contiguous and in the same relative position as in the staphylococcal plasmids in which *vat-vgb* are carried by a DNA fragment originating from the *E. faecalis* plasmid, pAM $\beta$ 1 (5).

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

Table 1. Relevant characteristics of the 51 *E. faecium* strains isolated in the Netherlands.

Strain		<i>Sg<sup>R</sup></i> genes	
designation	Origin (city)	Designation (1)	Size (in kb) of the hybridizing <i>Hind</i> III fragment (2)
4	pig (Weert)	vatD	1.8
14	pig (Weert)	vatD	1.8
17	pig (Weert)	satA	4.5*
18	pig (Weert)	satA	3.8*
19	pig (Weert)	satA	3.8*
K12	turkey	vatD	6.0*
K13	turkey	vatD	5.6*
K14	turkey	vatD	6.0*
K15	turkey	vatD	5.6*
K36	turkey	satA	6.0*
K40	turkey	vatD	3.6*
KS30	turkey	vatD	1.4
KS31	turkey	vatD	1.4
KS33	turkey	vatD	1.4
SK1	broiler	vatD	3.2*
SK2	broiler	vatD	3.2*
SK3	broiler	vatD	> 10*
SK6	broiler	satA	7.0*
SK7	broiler	vatD	5.6*
SK8	broiler	vatD	5.6*
SK13	broiler	vatD	3.2*

**PATENT**  
**Attorney Docket No. 03495-0193**

<i>Strain</i>		<i>Sg<sup>R</sup> genes</i>	
designation	Origin (city)	Designation (1)	Size (in kb) of the hybridizing <i>Hind</i> III fragment (2)
SK19	broiler	vatD	3.9*
PS17	broiler	vatD	4.3*
PS22	broiler	satA	4.0*
PS26	broiler	vatD	4.3*
PS35	broiler	vatD	4.3*
PS42	broiler	vatD	4.3*
KH2	turkey farmer	vatD	5.6*
KH4	turkey farmer	satA	3.9*
KH5	turkey farmer	vatD	7.3*
KH6	turkey farmer	vatD vat-vgb	5.6* 8.9
KH7	turkey farmer	vatD	2.5
KH15	turkey farmer	satA	2.3*
KH18	turkey farmer	vatD	2.3
KH19	turkey farmer	vatD	2.3
KH29	turkey farmer	vatD	2.3*
KH36	turkey farmer	satA	3.9
KH39	turkey farmer	vatD	2.9
LKH2	chicken farmer	satA	4.0*
LKH4	chicken farmer	satA	4.3*
SKH4	chicken farmer	vatD	2.5*
SKH8	chicken farmer	satA	5.6*
SKH11	chicken farmer	vatD	2.5

Strain		<i>Sg<sup>R</sup></i> genes	
designation	Origin (city)	Designation (1)	Size (in kb) of the hybridizing <i>Hind</i> III fragment (2)
SKH16	chicken farmer	satA	4.5*
SKH18	chicken farmer	satA	3.9*
SKH23	chicken farmer	satA	3.9*
M2	Suburban (Weert)	satA	3.9*
M5	suburban (Weert)	vatD	1.9
R2	suburban (Roermond)	satA	3.9*
R24	suburban (Roermond)	satA	3.9*
W3	suburban (Weert)	satA	4.0*

(1) The strains were screened for *Sg<sup>R</sup>* genes by hybridization at high annealing temperature (65°C) (2) with probe consisting of (i) recombinant plasmids containing DNA inserts from within each of the following genes: *vat*(9), *vatB* (3), *vatC* (6), *vga* (7) or *vgaB* (4) or (ii) DNA fragments amplified from *satA* (18) or *vatD* (this study) by PCR with the following pairs of primers: *sat1* (nt position: 189-210 in *satA*, Acc. No. L12033) and *sat2* (nt position: 760-782 in *sat\_* or *vatD*-F (nt position: 354-378 in *vatD*, Acc. No. AF153312) and *vatD*-R (nt position: 878-899 in *vatD*).

(2) The *Hind*III fragments indicated with an asterisk were detected in extrachromosomal DNA bands ( $\geq 40$  kb)

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, DC 20005  
202-408-4000

migrating above the chromosomal DNA fragments of the  
uncleaved total cellular DNA, in agarose gel  
electrophoresis in Tr- acetate buffer. In the other  
strains, the hybridizing bands comigrated with the  
chromosomal fragments, but the hybridization signals were  
as strong as those of the extrachromosomal DNA,  
suggesting that they may be carried plasmids.

Thirty-one of the tested *E. faecium* strains did not  
contain any of the eight genes investigated. PCR  
experiments were carried out at low annealing temperature  
(40°C) with a pair of degenerate primers, M and N (3,  
16), designed to amplify a DNA fragment from any sequence  
encoding a streptogramin A acetyltransferase containing  
two well conserved motifs, III and IV (3, 6, 16). A DNA  
fragment of the expected size (147 nt) was amplified from  
the cellular DNA of all the strains. The amplicon  
obtained with the strain K14 was sequenced using  
oligonucleotides M and N as primers. Its sequence was  
only 60.4 % to 68.6% similar to the SgA acetyltransferase  
genes (*vat*, *vatB*, *vatC*, *sata*), suggesting that the  
amplicon was from a different gene. A 5 kb *HindIII*  
fragment hybridizing with the sequenced amplicon was  
isolated from the cellular DNA of strain K14 and inserted  
into the *HindIII* site of pUC18. The resulting plasmid,  
pIP1798, was used to sequence 1080 nt of the insert  
including the sequences hybridizing with the 147 bp  
amplicon.

The sequence (registered in the GenBank EMBLdata  
Library under Accession No. AF153312) contains a 642 bp  
gene including an ATG start codon preceded, 6 nt  
upstream, by a putative ribosome-binding site. The free

## LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, DC 20005  
202-408-4000

energy of association of the most stable structure between this site and the 3' terminus of the 16S rRNA was -61.5 kJ/mol. This gene, named *vatD*, is similar to those encoding SgA acetyltransferases, *sataA*, *vat*, *vatB*, and *vatC* (54.3, 58.0, 60.0, and 60.1 % similarity, respectively). *vatD* encodes a putative 214 aa protein of 23,775 Da similar to xenobiotic acetyltransferases (17). It is most similar to the SgA acetyltransferases, *SatA*, *Vat*, *VatB*, and *VatC* (48.5, 50.0, 59.9 and 50.9 % identical amino acids, respectively).

Most *vat*-related genes in staphylococcal plasmids are contiguous to and downstream from another streptogramin-resistance (*Sg<sup>R</sup>*) gene. The pairs of genes are probably co-transcribed (12). However, analysis of the 270 and 170 nt sequences flanking *vatD* did not suggest the presence of any contiguous *Sg<sup>R</sup>* gene.

A DNA fragment of 858 nt containing *vatD* (nt 104 to nt 961, Accession No. AF153312) was amplified from pIP1798 and inserted between the *EcoRI* and *SmaI* sites of the shuttle vector, pOX7 (11). The resulting plasmid, pIP1801, introduced by electroporation in the *S. aureus* recipient, RN4220 (15), conferred resistance to pristinamycin IIA (MICs: 2 µg/ml for RN4220 [pOX7] and 8 µg/ml for RN4220 [pIP1801]).

The presence of *vatD* in other strains was tested by hybridization experiments at high stringency. Nucleotide sequences hybridizing with *vatD*-probe were detected in the 32 strains which did not carry *sataA*, including the strain containing *vat-vgb* (Table 1). Total cellular DNA of strain KH6 was subjected to agarose gel electrophoresis. The *vatD* and *vat-vgb* sequences migrated

to different positions, suggesting that they are not carried by the same plasmid.

The distribution of the streptogramin-resistance genes in the collection of *E. faecium* studied was clearly different from that found in staphylococci (2). It is worth checking whether the high prevalence of *vatD* in this collection, is also observed among infectious clinical isolates.

\* \* \*

In summary, the present invention pertains to polynucleotides derived from *Enterococcus faecium* genes encoding resistance to streptogramin A and chemically related compounds. This invention also relates to the use of the polynucleotides as oligonucleotide primers or probes for detecting *Enterococcus faecium* strains that are resistant to streptogramin A and related compounds in a biological sample.

In another embodiment, the present invention is directed to the full length coding sequences of the *Enterococcus faecium* genes encoding for resistance to streptogramin A and to the polypeptides expressed by these full length coding sequences.

Further, this invention relates to the use of the expressed polypeptides to produce specific monoclonal or polyclonal antibodies that serve as detection means in order to characterize any *Enterococcus faecium* strain carrying genes encoding resistance to streptogramin A and chemically related compounds.

The present invention is also directed to diagnostic methods for detecting specific strains of *Enterococcus faecium* expected to be contained in a biological sample.

The diagnostic methods use the oligonucleotide probes and primers as well as the antibodies of the invention raised against VatD protein or its fragments.

5 The invention relates also to a method of screening of molecules, which are capable to inactivate the acetyl transferase activity in bacteria. A bacterial culture, which is resistant to virginiamycin A, can grow in the presence of virginiamycin, but cannot grow if a new molecule active against acetyl transferase activity is  
10 added to the culture medium.

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205  
2206  
2207  
2208

REFERENCES

The following publications are cited herein. The entire disclosure of each publication is relied upon and incorporated by reference herein.

1. Aarestrup, F. M., F. Bager, N. E. Jensen, M. Madsen, A. Meyling, and H. C. Wegener. 1998. Surveillance of antimicrobial resistance in bacteria isolated from food animals to antimicrobial growth promoters and related therapeutic agents in Denmark. *APMIS* 106:606-622.
2. Allignet, J., S. Aubert, A. Morvan, and N. El Solh. 1996. Distribution of the genes encoding resistance to streptogramin A and related compounds among the staphylococci resistant to these antibiotics. *Antimicrob. Agents Chemother.* 40:2523-2528.
3. Allignet, J., and N. El Solh. 1995. Diversity among the Gram-positive acetyltransferases inactivating streptogramin A and structurally related compounds, and characterization of a new staphylococcal determinant, *vatB*. *Antimicrob. Agents Chemother.* 39:2027-2036.
4. Allignet, J., and N. El Solh. 1997. Characterization of a new staphylococcal gene, *vgaB*, encoding a putative ABC transporter conferring resistance to streptogramin A and related compounds. *Gene* 202:133-138.
5. Allignet, J., and N. El Solh. 1999. Comparative analysis of staphylococcal plasmids carrying three streptogramin-resistance genes : *vat-vgb-vga*. *Plasmid*.

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, CARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, DC 20005  
202-408-4000

6. Allignet, J., N. Liassine, and N. El Solh. 1998. Characterization of a staphylococcal plasmid related to pUB110, pIP1714, and carrying two novel genes, *vatC* and *vgbB*, encoding resistance to streptogramins A and B and similar antibiotics. *Antimicrob. Agents Chemother.* 42:1794-1798.
7. Allignet, J., V. Loncle, and N. El Solh. 1992. Sequence of a staphylococcal plasmid gene, *vga*, encoding a putative ATP-binding protein involved in resistance to virginiamycin A-like antibiotics. *Gene* 117:45-51.
8. Allignet, J., V. Loncle, P. Mazodier, and N. El Solh. 1988. Nucleotide sequence of a staphylococcal plasmid gene, *vgb*, encoding a hydrolase inactivating the B components of virginiamycin-like antibiotics. *Plasmid* 20:271-275.
9. Allignet, J., V. Loncle, C. Simenel, M. Delepierre, and N. El Solh. 1993. Sequence of a staphylococcal gene, *vat*, encoding an acetyltransferase inactivating the A-type compounds of virginiamycin-like antibiotics. *Gene* 130:91-98.
10. Cocito, C., M. Digambattista, E. Nyssen, and P. Vannuffel. 1997. Inhibition of protein synthesis by streptogramins and related antibiotics. *J. Antimicrob. Chemother.* 39 (Suppl. A):7-13.
11. Dyke, K., and S. Curnock. 1989. The nucleotide sequence of a small cryptic plasmid found in *Staphylococcus aureus* and its relationship to other plasmids. *FEMS Microbiol. Lett.* 58:209-216.

12. El Solh, N., and J. Allignet. 1998. Staphylococcal resistance to streptogramins and related antibiotics. Drug Resist. Updates 1:169-175.
13. Hammerum, A. M., L. B. Jensen, and F. M. Aarestrup. 1998. Detection of the *sata* gene and transferability of virginiamycin resistance in *Enterococcus faecium* from food-animals. FEMS Microbiol. Lett. 168:145-151.
14. Jensen, L. B., A. M. Hammerum, F. M. Aarestrup, A. E. van den Bogaard, and E. E. Stobberingh. 1998. Occurrence of *sata* and *vgb* genes in streptogramin-resistant *Enterococcus faecium* isolates of animal and human origins in The Netherlands. Antimicrob. Agents Chemother. 42:3330-3331.
15. Kreiswirth, B. N., S. Lofdahl, M. J. Betley, M. O'Reilly, P. E. Shlievert, M. S. Bergdoll, and R. P. Novick. 1983. The toxic shock exotoxin structural gene is not detectably transmitted by a prophage. Nature 306:709-712.
16. Liassine, N., J. Allignet, A. Morvan, S. Aubert, and N. El Solh. 1997. Analysis of pristinamycin-resistant staphylococci selected in an Algerian hospital by the extensive and inappropriate use of pristinamycin (Pt). Zbl. Bakt. 286:389-399.
17. Murray, I. A., and W. V. Shaw. 1997. O-acetyltransferases for chloramphenicol and other natural products. Antimicrob. Agents Chemother. 41:1-6.
18. Rende-Fournier, R., R. Leclercq, M. Galimand, J. Duval, and P. Courvalin. 1993. Identification of the *sata* gene encoding a streptogramin A

LAW OFFICES

FINNEGAN, HENDERSON,  
 FARABOW, GARRETT,  
 & DUNNER, L.L.P.  
 1300 I STREET, N.W.  
 WASHINGTON, DC 20005  
 202-408-4000

acetyltransferase in *Enterococcus faecium* BM4145.

Antimicrob. Agents Chemother. 37:2119-2125.

19. van den Bogaard, A. E., P. Mertens, N. H. London,  
and E. E. Stobberingh. 1997. High prevalence of  
colonization with vancomycin- and pristinamycin-  
resistant enterococci in healthy humans and pigs in  
The Netherlands: is the addition of antibiotics to  
animal feeds to blame? J. Antimicrob. Chemother.  
40:454-456.
20. van den Bogaard, A. E., L. B. Jensen, E.  
Stobberingh. 1997. An identical VRE isolated from  
a turkey and a farmer. New Eng. J. Med. 337:1558-  
1559.
21. Welton, L. A., L. A. Thal, M. B. Perri, S.  
Donabedian, J. McMahon, J. W. Chow, and M. J.  
Zervos. 1998. Antimicrobial resistance in  
enterococci isolated from turkey flocks fed  
virginiamycin. Antimicrob. Agents Chemother.  
42:705-708.

## LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

## SEQUENCE IDENTIFIERS

## SEQ ID NO:1

1 MTIPDANAIY HNSAIKEVVF IKNVIKSPNI EIGDYTYDD PVNPTDFEKH  
51 VTHHYEFLGD KLIIGKFCSL ASGIEFIMNG ANHVMKGIST YPFNILGGDW  
5 101 QQYTPELTDL PLKGD TVVGN DVWFGQNVTV LPGVKIGDGA IIGANSVVTK  
151 DVAPYTIVGG NPIQLIGPRF EPEVIQALEN LAWWNKDIEW ITANVPKLMQ  
201 TTPITLELINS LME

## SEQ ID NO:2

10 ATGACTATAC CTGACGCAAA TGCAATCTAT CATAACTCAG CCATCAAAGA GGTGTCTTT  
ATCAAGAACG TGATCAAAAG TCCCAATATT GAAATTGGGG ACTACACCTA TTATGATGAC  
CCAGTAAATC CCACCGATTT TGAGAAACAC GTTACCCATC ACTATGAATT TCTAGGCGAC  
AAATTAATCA TCGGTAAATT TTGTTCTCTC GCCAGTGGCA TTGAATTTAT CATGAACGGT  
GCCAACCACG TAATGAAAGG TATTTGACT TATCCATTTA ATATATTAGG TGGCGATTGG  
15 CAACAATACA CTCCTGAACT GACTGATTTG CCGTTGAAAG GTGATACTGT AGTCGGAAAT  
GACGTGTGGT TTGGGCAAAA TGTGACCGTC CTACCAGGCG TAAAAATAGG TGACGGTGCC  
ATTATCGGAG CAAATAGTGT TGTAACAAAA GACGTCGCTC CATATACAAT TGTCGGTGCC  
AATCCAATTC AACTCATCGG ACCAAGATTT GAACCGGAAG TTATTCAAGC ATTAGAAAAT  
CTGGCATGGT GGAATAAAGA TATTGAATGG ATAACGCTA ATGTTCTAA ACTAATGCAA  
ACAACACCCA CACTTGAATT GATAAACAGT TTAATGGAAA AA

20 5'- CAATATTGGAATTCGGGACTACACC - 3' primer F SEQ ID NO:3  
EcoRI

5'- CTGTTTATGAATTCAGTGTGG - 3' primer R SEQ ID NO:4  
EcoRI

Seq. 4  
25 I M N G A N H SEQ ID NO:5

5'- ATH ATG AAY GCN AAY CAY - 3' primer M SEQ ID NO:6

G N D V W SEQ ID NO:7

5'- CCA NAC RTC RTT NCC - 3' primer N SEQ ID NO:8

(abbreviations: H=A,T,C Y=C,T N=A,C,T,G R=A,G)

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

PATENT  
Attorney Docket No. 03495-0193

A N A I Y H N S SEQ ID NO:9

5'- GCA AAT GCA ATC TAT CAT AAC TCA - 3' SEQ ID NO:10

M Q T T P T L E L SEQ ID NO:11

5'- ATG CAA ACA ACA CCC ACA CTT GAA TTG - 3' SEQ ID NO:12

5 5'- TAGAAAGAATTCAGTGATTGTGG - 3' primer A SEQ ID NO:13  
EcoRI

5'- GGATTCACTAAATAGTAAAGGCCGTG - 3' primer B SEQ ID NO:14  
HaeIII

SEQ ID NO:15

10 AAATTTAGG CGCACAAAAA GAAAGAGTGT GACAAAACAT GGTTATGCTA CATGTTTAAAG  
GTAAAAATAG TTATGTCACA ACTACTTATT TTTTACCCA ATCTTCTAGA CTATAATTAA  
AATTAAATAA CTCAATTCGG AGGTACTAAC CTGACTATAC CTGACGCAA TGCAATCTAT  
CATAACTCAG CCATCAAAGA GGTGACTTT ATCAAGAACG TGATCAAAAG TCCCAATATT  
15 GAAATTGGGG ACTACACCTA TTATGATGAC CCAGTAAATC CCACCGATTT TGAGAAACAC  
GTTACCCATC ACTATGAATT TCTAGGCGAC AAATTAATCA TCGGTAAATT TTGTTCTCTC  
GCCAGTGGCA TTGAATTTAT CATGAACGGT GCCAACCACG TAATGAAAGG TATTTCGACT  
TATCCATTTA ATATATTAGG TGGCGATTGG CAACAATACA CTCCTGAACT GACTGATTTG  
CCGTTGAAAG GTGATACTGT AGTCGGAAAT GACGTGTGGT TTGGGCAAAA TGTGACCGTC  
CTACCAGGCG TAAAAATAGG TGACGGTGCC ATTATCGGAG CAAATAGTGT TGTAACAAAA  
20 GACGTCGCTC CATATACAAT TGTCCGTGGC AATCCAATTC AACTCATCGG ACCAAGATTT  
GAACCGGAAG TTATTCAAGC ATTAGAAAAT CTGGCATGGT GGAATAAAGA TATTGAATGG  
ATAACTGCTA ATGTTCTTAA ACTAATGCAA ACAACACCCA CACTTGAATT GATAAACAGT  
TTAATGGAAA AATAAAAACA AAAAAGCCGT GCAAGCAATC CAAAAATGAT TGTTTACACG  
G

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, DC 20005  
202-408-4000

WHAT IS CLAIMED IS:

1. A purified nucleic acid molecule comprising the DNA sequence of SEQ ID NO:2.

2. A purified nucleic acid molecule encoding an amino acid sequence comprising the sequence of SEQ ID NO:1.

3. A purified nucleic acid molecule that hybridizes to either strand of a denatured, double-stranded DNA comprising the nucleic acid sequence of any one of claims 1 or 2 under conditions of moderate stringency.

4. The purified nucleic acid molecule as claimed in claim 3, wherein said isolated nucleic acid molecule is derived by *in vitro* mutagenesis from SEQ ID NO:2 to NO 15.

5. A purified nucleic acid molecule degenerate from SEQ ID NOS:5, 6, 7, or 8 as a result of the genetic code.

6. A purified nucleic acid molecule, which encodes vatD polypeptide, an allelic variant of vatD polypeptide DNA, or a homolog of vatD polypeptide DNA.

7. A recombinant vector that directs the expression of a nucleic acid molecule selected from the group consisting of the purified nucleic acid molecules of claims 1, 2, 5, and 6.

8. A recombinant vector that directs the expression of a nucleic acid molecule of claim 3.

9. A recombinant vector that directs the expression of a nucleic acid molecule of claim 4.

## LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

10. A purified polypeptide encoded by a nucleic acid molecule selected from the group consisting of the purified nucleic acid molecules of claims 1, 2, 5, and 6.

11. A purified polypeptide according to claim 10 having a molecular weight of approximately 23,775 kDa as determined by SDS-PAGE.

12. A purified polypeptide according to claim 10 in non-glycosylated form.

13. A purified polypeptide encoded by a nucleic acid molecule of claim 3.

14. A purified polypeptide according to claim 13 in non-glycosylated form.

15. A purified polypeptide encoded by a nucleic acid molecule of claim 4.

16. A purified polypeptide according to claim 15 in non-glycosylated form.

17. Purified antibodies that bind to a polypeptide of claim 10.

18. Purified antibodies according to claim 17, wherein the antibodies are monoclonal antibodies.

19. Purified antibodies that bind to a polypeptide of claim 13.

20. Purified antibodies according to claim 19, wherein the antibodies are monoclonal antibodies.

21. Purified antibodies that bind to a polypeptide of claim 15.

22. Purified antibodies according to claim 21, wherein the antibodies are monoclonal antibodies.

23. A host cell transfected or transduced with the vector of claim 7.

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, DC 20005  
202-408-4000

24. A method for the production of vatD polypeptide comprising culturing a host cell of claim 23 under conditions promoting expression, and recovering the polypeptide from the culture medium.

5        25. The method of claim 24, wherein the host cell is selected from the group consisting of bacterial cells, yeast cells, plant cells, and animal cells.

26. A host cell transfected or transduced with the vector of claim 8.

10       27. A method for the production of vatD polypeptide comprising culturing a host cell of claim 26 under conditions promoting expression, and recovering the polypeptide from the culture medium.

15       28. The method of claim 27, wherein the host cell is selected from the group consisting of bacterial cells, yeast cells, plant cells, and animal cells.

29. A host cell transfected or transduced with the vector of claim 9.

20       30. A method for the production of vatD polypeptide comprising culturing a host cell of claim 29 under conditions promoting expression, and recovering the polypeptide from the culture medium.

25       31. The method of claim 30, wherein the host cell is selected from the group consisting of bacterial cells, yeast cells, plant cells, and animal cells.

32. The plasmid deposited at CNCM under the Accession Number I-2247.

33. An immunological complex comprising a vatD polypeptide and an antibody that specifically recognizes said polypeptide.

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, DC 20005  
202-408-4000

34. A method of detecting a bacterium in a biological sample that harbors a polynucleotide sequence according to claim 1, said method comprising the steps of:

- a) contacting bacterial DNA of the biological sample with a primer or a probe according to claim 1 or 3 to 6, which hybridizes with a nucleotide sequence encoding resistance to streptogramins;
- b) amplifying the nucleotide sequence using said primer or said probe; and
- c) detecting a hybridized complex formed between said primer or probe and the DNA.

35. A kit for detecting a bacterium that is resistant to a streptogramin and harbors a polynucleotide sequence according to claim 1, said kit comprising:

- a) a polynucleotide probe according to claim 19 or 20; and
- b) reagents to perform a nucleic acid hybridization reaction.

36. A kit for detecting a bacterium that is resistant to a streptogramin and harbors a polynucleotide sequence according to claim 2, said kit comprising:

- a) a polynucleotide probe according to claim 19 or 20; and
- b) reagents to perform a nucleic acid hybridization reaction.

37. A method of screening an active antibiotic for treating a Gram-positive bacterial infection, comprising the steps of:

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, DC 20005  
202-408-4000

- a) contacting the antibiotic with Gram-positive bacteria that are resistant to a streptogramin and contain a polynucleotide sequence according to claim 1; and
- 5 b) determining the activity of the antibiotic on the bacteria.

38. A method of screening for active synthetic molecules capable of penetrating into a bacteria of the enterococcus family, wherein an inhibiting activity of the molecules is tested on at least a polypeptide encoded by a polynucleotide sequence according to claim 1, the method comprising the steps of:

- a) contacting a sample of said active molecules with the bacteria;
- 15 b) testing the capacity of the active molecules to penetrate into the bacteria and the capacity of inhibiting a bacterial culture at various concentration of the molecules; and
- c) choosing the active molecule that provides an inhibitory effect of at least 80% on the bacterial culture compared to an untreated culture.

39. An *in vitro* method of screening for active molecules capable of inhibiting a polypeptide encoded by a polynucleotide sequence according to claim 1, said method comprising the steps of:

- a) contacting the active molecules with said polypeptide;
- 25 b) testing the capacity of the active molecules, at various concentrations, to inhibit the activity of the polypeptide; and

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, DC 20005  
202-408-4000

- c) choosing the active molecule that provides an inhibitory effect of at least 80 % on the activity of the said polypeptide.

40. A method of detecting a bacterium in a biological sample that harbors a polynucleotide sequence according to claim 2, said method comprising the steps of:

- a) contacting said sample with an antibody according to claim 17 that recognizes a polypeptide encoded by said polynucleotide sequences; and
- b) detecting a complex formed between the antibody and the polypeptide.

41. A diagnostic kit for *in vitro* detection of a bacterium harboring the polynucleotide sequences according to claim 2, said kit comprising:

- a) a predetermined quantity of monoclonal or polyclonal antibodies according to claim 17;
- b) reagents to perform an immunological reaction between the antibodies and a polypeptide encoded by said polynucleotide sequences; and
- c) reagents for detecting a complex formed between the antibodies and the polypeptide encoded by said polynucleotide sequences.

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

A gene encoding an acetyltransferase inactivating streptogramin A was isolated from an *Enterococcus faecium* strain and sequenced. The gene, designated vatD, encodes a 23,775 kDa protein exhibiting 48.5 to 59.9 % amino acid identity with four other enzymes with the same activity, Vat, VatB, VatC and SatA.

1 CCCTTTAAAG AGGGCTTTTA TATATTAATC ACAAATCACT TATCACAAAT  
 51 CACAAGTGAT TTGTGATTGT TGATGATAAA ATAAGAATAA GAAGAAATAG  
 101 AAAGAAGTGA GTGATTGTGG GAAATTTAGG CGCACAAAAA GAAAGAGTGT  
 151 GACAAAACAT GGTTATGCTA CATGTTTAAG GTAAAAATAG TTATGTCACA  
 201 ACTACTTATT TTTTACCCTA ATCTTCTAGA CTATAATTAA AATTAAATAA  
 XbaI  
 M T I P D A N A I Y  
 251 CTCAATTCGG AGGTACTAAC ATGACTATAC CTGACGCAA TGCAATCTAT  
 RBS START  
 H N S A I K E V V F I K N V I K S  
 301 CATAACTCAG CCATCAAAGA GGTGTCTTT ATCAAGAACG TGATCAAAAG  
 DdeI DpnI  
 P N I E I G D Y T Y Y D D P V N  
 351 TCCCAATATT GAAATTGGGG ACTACACCTA TTATGATGAC CCAGTAAATC  
 SspI  
 P T D F E K H V T H H Y E F L G D  
 401 CCACCGATTT TGAGAAACAC GTTACCCATC ACTATGAATT TCTAGGCGAC  
 K L I I G K F C S L A S G I E F I  
 451 AAATTAATCA TCGGTAAATT TTGTTCTCTC GCCAGTGGCA TTGAATTTAT  
 M N G A N H V M K G I S T Y P F  
 501 CATGAACGGT GCCAACCACG TAATGAAAGG TATTTCGACT TATCCATTTA  
 TaqI  
 N I L G G D W Q Q Y T P E L T D L  
 551 ATATATTAGG TGGCGATTGG CAACAATACA CTCCTGAAC TACTGATTGG  
 P L K G T V V G N D V W F G Q N V  
 601 CCGTTGAAAG GTGATACTGT AGTCGGAAAT GACGTGTGGT TTGGGCAAAA  
 T V L P G V K I G D G A I I G A  
 651 TGTGACCGTC CTACCAGGCG TAAAAATAGG TGACGGTGCC ATTATCGGAG  
 N S V V T K D V A P Y T I V G G N  
 701 CAAATAGTGT TGTAACAAAA GACGTCGCTC CATATACAAT TGTCGGTGGC  
 P I Q L I G P R F E P E V I Q A L  
 751 AATCCAATTC AACTCATCGG ACCAAGATTT GAACCGGAAG TTATTCAAGC  
 XmnI  
 E N L A W W N K D I E W I T A N  
 801 ATTAGAAAAT CTGGCATGGT GGAATAAAGA TATTGAATGG ATAAGTCTA  
 N V P K L M Q T T P T L E L I N S  
 851 ATGTTCTTAA ACTAATGCAA ACAACACCCA CACTTGAATT GATAAACAGT  
 L M E K \*  
 STOP  
 901 TTAATGGAAA AATAAAAACA AAAAAGCCGT GCAAGCAATC CAAAAATGAT  
 951 TGTTTACACG GCCTTTACTA TTAGTGAAT CCAATTTATT AATAATAGAT  
 HaeIII  
 1001 ATGATATACC AGTAAAAAAT AACTAGCCA CCTCTGGCGG TACTCTACTC  
 1051 GTATATTTTA TTACGACCT TCTGATGATA

FIGURE 1



1080 bp : restriction map




FIGURE3